Voyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wedbush Remains Bullish on Voyager Therapeutics (VYGR) Following 4Q Financials
March 18, 2016 8:29 AM EDTWedbush reiterated an Outperform rating and $36.00 price target on Voyager Therapeutics (NASDAQ: VYGR) following 4Q financial results.
Analyst David Nierengarten commented, "VYGR reported net income of ($8.8M), below our estimate of ($6.1M) in part due to GAAP expenses of $1.5M related to pre-IPO... More
Voyager Therapeutics (VYGR) Misses Q4 EPS by 12c
March 17, 2016 8:25 AM EDTVoyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.67), $0.12 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $4.94 million versus the consensus estimate of $3.73 million.
Cash, cash equivalents and marketable securities as of December 31, 2015 were approximately $224 million, compared to $161 million on September... More
